SG11201507759WA - Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers - Google Patents
Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancersInfo
- Publication number
- SG11201507759WA SG11201507759WA SG11201507759WA SG11201507759WA SG11201507759WA SG 11201507759W A SG11201507759W A SG 11201507759WA SG 11201507759W A SG11201507759W A SG 11201507759WA SG 11201507759W A SG11201507759W A SG 11201507759WA SG 11201507759W A SG11201507759W A SG 11201507759WA
- Authority
- SG
- Singapore
- Prior art keywords
- isoindoline
- dioxo
- dione
- piperidine
- amino
- Prior art date
Links
- 201000007455 central nervous system cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361807605P | 2013-04-02 | 2013-04-02 | |
| PCT/US2014/032483 WO2014165482A1 (en) | 2013-04-02 | 2014-04-01 | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507759WA true SG11201507759WA (en) | 2015-10-29 |
Family
ID=50588939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507759WA SG11201507759WA (en) | 2013-04-02 | 2014-04-01 | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9839632B2 (enExample) |
| EP (1) | EP2981262A1 (enExample) |
| JP (1) | JP6469077B2 (enExample) |
| KR (1) | KR20150136078A (enExample) |
| CN (1) | CN105246480A (enExample) |
| AU (1) | AU2014248263A1 (enExample) |
| BR (1) | BR112015025252A2 (enExample) |
| CA (1) | CA2907908A1 (enExample) |
| EA (1) | EA201591902A1 (enExample) |
| HK (1) | HK1219896A1 (enExample) |
| MX (1) | MX2015013912A (enExample) |
| PH (1) | PH12015502266A1 (enExample) |
| SG (1) | SG11201507759WA (enExample) |
| WO (1) | WO2014165482A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7143295B2 (ja) | 2016-11-24 | 2022-09-28 | ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 |
| CN107875128A (zh) * | 2017-12-06 | 2018-04-06 | 佛山市弘泰药物研发有限公司 | 一种泊马度胺口崩片及其制备方法 |
| WO2019136016A1 (en) * | 2018-01-02 | 2019-07-11 | Celgene Corporation | Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| CN115671295B (zh) * | 2019-10-21 | 2025-10-28 | 新基公司 | 包含化合物的药物组合物及其使用方法 |
| JP7581345B2 (ja) | 2019-10-21 | 2024-11-12 | セルジーン コーポレーション | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて慢性リンパ性白血病を治療する方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| BR0110364A (pt) * | 2000-04-25 | 2003-12-30 | Idec Pharma Corp | Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central |
| ATE374609T1 (de) * | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
| KR100915483B1 (ko) | 2000-12-06 | 2009-09-03 | 로버트 제이 하리리 | 태반 줄기 세포의 회수 방법 |
| JP2004528021A (ja) | 2001-02-14 | 2004-09-16 | アンスロジェネシス コーポレーション | 分娩後の哺乳動物の胎盤、その使用およびそれに由来する胎盤幹細胞 |
| US20120322779A9 (en) | 2001-04-25 | 2012-12-20 | Rhonda Voskuhl | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2672000C (en) * | 2002-05-17 | 2011-11-29 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| KR20120039065A (ko) | 2003-12-02 | 2012-04-24 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| BRPI0509019A (pt) | 2004-03-22 | 2007-08-07 | Celgene Corp | métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit |
| WO2006060507A2 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| CA2612612C (en) | 2005-06-30 | 2014-03-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
| US8715677B2 (en) | 2005-09-01 | 2014-05-06 | Celgene Corporation | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| US20070066512A1 (en) | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| US20070155791A1 (en) | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| US20080051431A1 (en) | 2006-05-26 | 2008-02-28 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds in combination therapy |
| CA2665778A1 (en) | 2006-10-19 | 2008-05-15 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases |
| US20090232776A1 (en) | 2007-11-08 | 2009-09-17 | Moutouh-De Parseval Laure A | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction |
| JP2011505808A (ja) | 2007-12-07 | 2011-03-03 | セルジーン コーポレイション | 非ホジキンリンパ腫の治療の間における、免疫調節化合物に対する細胞の感受性を予測するためのバイオマーカー |
| US20100098657A1 (en) | 2007-12-27 | 2010-04-22 | Schafer Peter H | Method of Treating Cancer with Immunomodulatory Compounds and IgG |
| WO2009105256A2 (en) | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| EP3351240B1 (en) * | 2009-05-19 | 2019-04-10 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| CN104902754A (zh) | 2012-11-05 | 2015-09-09 | 细胞基因公司 | 在肾损伤的受试者中用泊马度胺治疗癌症 |
-
2014
- 2014-04-01 US US14/781,898 patent/US9839632B2/en active Active
- 2014-04-01 EP EP14720035.6A patent/EP2981262A1/en not_active Withdrawn
- 2014-04-01 AU AU2014248263A patent/AU2014248263A1/en not_active Abandoned
- 2014-04-01 BR BR112015025252A patent/BR112015025252A2/pt not_active IP Right Cessation
- 2014-04-01 KR KR1020157027212A patent/KR20150136078A/ko not_active Withdrawn
- 2014-04-01 CN CN201480030076.7A patent/CN105246480A/zh active Pending
- 2014-04-01 JP JP2016506360A patent/JP6469077B2/ja active Active
- 2014-04-01 MX MX2015013912A patent/MX2015013912A/es unknown
- 2014-04-01 HK HK16108025.4A patent/HK1219896A1/zh unknown
- 2014-04-01 CA CA2907908A patent/CA2907908A1/en not_active Abandoned
- 2014-04-01 WO PCT/US2014/032483 patent/WO2014165482A1/en not_active Ceased
- 2014-04-01 EA EA201591902A patent/EA201591902A1/ru unknown
- 2014-04-01 SG SG11201507759WA patent/SG11201507759WA/en unknown
-
2015
- 2015-09-29 PH PH12015502266A patent/PH12015502266A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2907908A1 (en) | 2014-10-09 |
| EP2981262A1 (en) | 2016-02-10 |
| EA201591902A1 (ru) | 2016-02-29 |
| MX2015013912A (es) | 2016-08-12 |
| JP6469077B2 (ja) | 2019-02-13 |
| AU2014248263A1 (en) | 2015-10-15 |
| WO2014165482A1 (en) | 2014-10-09 |
| HK1219896A1 (zh) | 2017-04-21 |
| JP2016515621A (ja) | 2016-05-30 |
| US20160045484A1 (en) | 2016-02-18 |
| CN105246480A (zh) | 2016-01-13 |
| BR112015025252A2 (pt) | 2017-07-18 |
| KR20150136078A (ko) | 2015-12-04 |
| PH12015502266A1 (en) | 2016-02-01 |
| US9839632B2 (en) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201601024B (en) | Methods and compositions for treating brain diseases | |
| IL251066B (en) | Preparations and methods for the treatment of metabolic disorders | |
| ZA201602839B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL245042A0 (en) | Treatment with proton tyrosine kinase inhibitors and immunotherapy | |
| ZA201700311B (en) | Compositions and methods of use for treating metabolic disorders | |
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| IL259861A (en) | Methods and preparations for the treatment of disorders related to seizures | |
| EP2986306A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
| IL244182B (en) | Preparations, methods and systems for the treatment of skin disorders | |
| IL259025B (en) | A combination of rxr agonists and thyroid hormones for the treatment of diseases of the nervous system | |
| SG10202013034QA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| IL239921A0 (en) | Preparations containing solutions in solid state and their use for the treatment of pain | |
| EP2897689A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALOPEZIA | |
| EP2989123A4 (en) | METHODS AND COMPOSITIONS FOR TREATING COAGULATION DISORDERS | |
| IL239374B (en) | Preparations and methods for treating brain tumors | |
| SG11201507759WA (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
| PL2968478T3 (pl) | Kompozycje i sposoby do leczenia karboksyhemoglobinemii | |
| MX394633B (es) | Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamina (nmda) | |
| EP3307775A4 (en) | Methods for diagnosing and treating affective disorders | |
| PL3377089T3 (pl) | Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego |